Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GNPX 
Genprex Inc (GNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: GNPX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.5
1 Year Target Price $7.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -33.55% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 6.76M USD | Price to earnings Ratio 0.1 | 1Y Target Price 7.5 |
Price to earnings Ratio 0.1 | 1Y Target Price 7.5 | ||
Volume (30-day avg) 1 | Beta -0.8 | 52 Weeks Range 2.70 - 63.00 | Updated Date 11/22/2025 |
52 Weeks Range 2.70 - 63.00 | Updated Date 11/22/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 42.5 |
Earnings Date
Report Date 2025-11-14 | When - | Estimate -0.65 | Actual -5 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -207.41% | Return on Equity (TTM) -612.3% |
Valuation
Trailing PE 0.1 | Forward PE - | Enterprise Value 5276357 | Price to Sales(TTM) - |
Enterprise Value 5276357 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.18 | Shares Outstanding 1631841 | Shares Floating 668212 |
Shares Outstanding 1631841 | Shares Floating 668212 | ||
Percent Insiders 1.18 | Percent Institutions 1.56 |
Upturn AI SWOT
Genprex Inc
Company Overview
History and Background
Genprex, Inc. is a clinical-stage gene therapy company founded in 2009 focused on developing therapies for cancer and diabetes. It aims to provide new treatment approaches based on unique mechanisms of action.
Core Business Areas
- Oncology: Development of gene therapies targeting various cancers, with a focus on lung cancer and other solid tumors.
- Diabetes: Development of gene therapies aimed at addressing Type 1 and Type 2 diabetes.
Leadership and Structure
The leadership team includes Rodney Varner (Chairman and CEO) and other executives specializing in clinical development, regulatory affairs, and finance. The organizational structure reflects a typical biotech company with functional departments and project-based teams.
Top Products and Market Share
Key Offerings
- REPLiCOR: A gene therapy candidate for non-small cell lung cancer (NSCLC). REPLiCOR aims to deliver the TUSC2 tumor suppressor gene to cancer cells. Market share data is not readily available, as it is still in clinical trials. Competitors include companies developing targeted therapies, immunotherapies, and other gene therapies for NSCLC (e.g., AstraZeneca's Tagrisso, Merck's Keytruda, Amgen's Imlygic).
- GPX-002: A gene therapy candidate for type 1 and type 2 diabetes. GPX-002 aims to reprogram pancreatic cells to produce insulin. Market share data is not available as GPX-002 is in preclinical development. Competitors include companies developing innovative diabetes therapies such as Vertex Pharmaceuticals.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing success in clinical trials. The oncology and diabetes fields represent significant unmet medical needs and large market opportunities.
Positioning
Genprex is positioned as a player in the gene therapy market, focusing on innovative approaches for cancer and diabetes. Its competitive advantage lies in its unique gene therapy platforms.
Total Addressable Market (TAM)
The global gene therapy market is estimated at billions of dollars, with significant potential in oncology and diabetes. Genprex is positioned to capture a portion of this TAM with successful clinical development and commercialization.
Upturn SWOT Analysis
Strengths
- Proprietary gene therapy platforms
- Focus on unmet medical needs
- Experienced leadership team
- Potential for breakthrough therapies
Weaknesses
- Limited financial resources
- Early-stage clinical development
- Dependence on clinical trial success
- Relatively small team
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Positive clinical trial results
- Increased investor interest in gene therapy
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger companies
- Financial market volatility
Competitors and Market Share
Key Competitors
- AZN
- MRK
- VRTX
Competitive Landscape
Genprex faces competition from larger, well-established pharmaceutical companies with greater resources. Genprex needs to show clinical success to show efficacy against larger pharma.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in the advancement of its clinical pipeline and expansion of its intellectual property portfolio.
Future Projections: Future growth depends on clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst projections are available from financial data providers.
Recent Initiatives: Recent initiatives include advancing REPLiCOR in clinical trials, expanding its intellectual property portfolio, and exploring strategic partnerships.
Summary
Genprex is a clinical-stage gene therapy company with potential in cancer and diabetes treatments, but its early development stage and limited resources present challenges. Success hinges on clinical trial outcomes and strategic partnerships. The company's focus on unmet medical needs provides opportunities for growth, but it must navigate regulatory hurdles and compete with larger industry players. Its progress with REPLiCOR for NSCLC is promising, while its diabetes program is in earlier stages. The company needs to manage its cash carefully.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Genprex Inc. SEC Filings (10-K, 10-Q)
- Company Website
- Financial News Sources
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Genprex Inc
Exchange NASDAQ | Headquaters Austin, TX, United States | ||
IPO Launch date 2018-03-29 | President, CEO, CFO & Director Mr. Ryan M. Confer M.S. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.genprex.com |
Full time employees 13 | Website https://www.genprex.com | ||
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company's technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Its three-lung cancer clinical programs have received a Fast Track Designation from the FDA for the treatment of that patient population, and SCLC program has received an FDA Orphan Drug Designation. The company's diabetes gene therapy comprises of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, its GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which produce insulin but distinct enough from beta cells to evade the body's immune system; and GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. It has research agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive. Genprex, Inc. was incorporated in 2009 and is based in Austin, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.